Atlas Trials

IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC)

Clinical trial NCT06078657 · UNKNOWN

Trial details

NCT number
NCT06078657
Sponsor
The First Affiliated Hospital of Zhengzhou University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Esophageal Squamous Cell Carcinoma (ESCC)PD-1 Inhibitors
Start date
2023-10-01
Primary completion
2024-10-01
Enrollment
46

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.